[1]许欣颖,胡小海,朱红俊.柴归汤调控环磷酸腺苷/蛋白激酶B信号通路干预原发性高血压大鼠作用机制[J].陕西中医,2024,(3):313-317.[doi:DOI:10.3969/j.issn.1000-7369.2024.03.005]
　XU Xinying,HU Xiaohai,ZHU Hongjun.Mechanism of Chaigui decoction's modulation of cAMP/AKT signaling pathway in intervening blood pressure in spontaneously hypertensive rats[J].,2024,(3):313-317.[doi:DOI:10.3969/j.issn.1000-7369.2024.03.005]
点击复制

柴归汤调控环磷酸腺苷/蛋白激酶B信号通路干预原发性高血压大鼠作用机制
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2024年3期
页码:
313-317
栏目:
基础研究
出版日期:
2024-03-05

文章信息/Info

Title:
Mechanism of Chaigui decoction's modulation of cAMP/AKT signaling pathway in intervening blood pressure in spontaneously hypertensive rats
作者:
许欣颖1; 胡小海1; 朱红俊2
(1.南京中医药大学,江苏 南京 210023; 2.南京中医药大学无锡附属医院,江苏 无锡 214071)
Author(s):
XU Xinying; HU Xiaohai; ZHU Hongjun
(Nanjing University of Chinese Medicine,Nanjing 210023,China)
关键词:
高血压;  柴归汤;  环磷酸腺苷;  蛋白激酶B;  蛋白激酶A;  一氧化氮合酶
Keywords:
Hypertension;  Chaigui decoction;  Cyclic adenosine monophosphate;  Protein kinase B;  Protein kinase A;  Nitric oxide synthase
分类号:
R 544.1
DOI:
DOI:10.3969/j.issn.1000-7369.2024.03.005
文献标志码:
A
摘要:
目的:探讨柴归汤对原发性高血压大鼠环磷酸腺苷(cAMP)/蛋白激酶B(AKT)通路表达的影响,分析其降压机制。方法:Wistar-Kyoto大鼠作为空白组。将原发性高血压大鼠随机分为模型组、贝那普利组,柴归汤入肠成分组、柴归汤高剂量组、柴归汤中剂量组、柴归汤低剂量组,并进行对应药物的灌胃治疗。给药28 d,检测各组大鼠血压; 采用酶联免疫吸附测定法检测大鼠血清中cAMP水平及主动脉组织蛋白激酶B(AKT)、蛋白激酶A(PKA); 应用PEX100磷酸化抗体芯片进行磷酸化检测分析。结果:给药后,柴归汤高剂量组、柴归汤中剂量组、柴归汤低剂量组、柴归汤入肠成分组及贝那普利组在干预4周后的收缩压、舒张压均降低(P<0.01)。与空白组相比,柴归汤入肠成分组cAMP、柴归汤低剂量组、柴归汤中剂量组PKA及贝那普利组AKT均有所升高(均P<0.05)。与模型组相比,柴归汤入肠成分组血清cAMP水平,柴归汤高剂量组、柴归汤中剂量组主动脉组织AKT水平,柴归汤中剂量组主动脉组织PKA水平均升高(均P<0.05)。结论:柴归汤可降低原发性高血压大鼠血压,上调大鼠血清cAMP、主动脉组织AKT、PKA水平,其降压机制可能与cAMP/AKT、cAMP/PKA级联介导信号相关。
Abstract:
Objective:To investigate effect of Chaigui decoction on expression of cyclic adenosine monophosphate(cAMP)/protein kinase B(AKT)pathway,thus mechanism of lowering blood pressure.Methods:Wistar-Kyoto rats were used as blank group.Spontaneously hypertensive(SH)rats were randomly divided into model group,Benadryl group,Chaigui decoction intestinal component group,high-dose Chaigui decoction group,medium-dose Chaigui decoction group,low-dose Chaigui decoction group,which were treated with corresponding medication in the gastric gavage.The blood pressure of each group were measured after 28 days of administration.cAMP level in serum,AKT and protein kinase A(PKA)levels in aortic tissues were detected by ELISA.Phosphorylation was detected by PEX100 phosphorylation antibody microarray.Results:After dosing 4 weeks,the high-dose Chaigui decoction group,the medium-dose Chaigui decoction group,and the low-dose Chaigui decoction group,the Chaigui decoction intestinal component group,and the Benadryl group were significantly reduced systolic and diastolic blood pressures(P<0.01).Compared with the blank group,cAMP in the Chaigui decoction intestinal component group,PKA in the low-dose Chaigui decoction group and middle-dose Chaigui decoction group and AKT in the Benadryl group were all increased(all P<0.05).Compared with the model group,the cAMP level in the Chaigui decoction intestinal component group,the level of AKT in the aortic tissues of the high-dose Chaigui decoction group and middle-dose Chaigui decoction group,and the PKA level in the aortic tissues of the middle-dose group Chaigui decoction were all increased(all P<0.05).Conclusion:Chaigui decoction can reduce blood pressure,upregulate cAMP level in serum,and AKT、PKA levels in aortic tissues of SH rats.Its antihypertensive mechanism may be related to cAMP/AKT and cAMP/PKA cascade mediated signals.

参考文献/References:

[1] XUE B,JOHNSON A K.Sensitization of hypertension the impact of earlier life challenges:Excellence award for hypertension research 2021[J].Hypertension,2023,80(1):1-12.
[2] ZHOU B,PEREL P,MENSAH G A,et al.Global epidemiology health burden and effective interventions for elevated blood pressure and hypertension[J].Nature Reviews Cardiology,2021,18(11):785-802.
[3] TRAN K B,LANG J J,COMPTON K,et al.The global burden of cancer attributable to risk factors 2010-19:A systematic analysis for the global burden of disease study 2019[J].The Lancet,2022,400(10352):563-591.
[4] 中国高血压防治指南修订委员会,高血压联盟(中国),中华医学会心血管病学分会,等.中国高血压防治指南(2018年修订版)[J].中国心血管杂志,2019,24(1):24-56.
[5] HAO P,JIANG F,CHENG J,et al.Traditional Chinese medicine for cardiovascular disease:Evidence and potential mechanisms[J].Journal of the American College of Cardiology,2017,69(24):2952-2966.
[6] 张卫丽,张卫红,刘海立,等.基于ox-LDL信号通路探讨桑芪滋阴补肾汤对人脐静脉血管内皮细胞的影响及其作用机制[J].陕西中医,2023,44(9):1193-1197.
[7] ZI L L,FENG J C,HUA Q,et al.Effects of Qingda granule on patients with grade 1 hypertension at low-medium risk:study protocol for a randomized controlled double-blind clinical trial[J].Trials,2023,24(1):1-7.
[8] JING R G,HONGYUN Z,HAN Y,et al.Based on the theory of Five Yun Six Qi to study the clinical effect of Chaigui decoction on Jueyin type hypertension[J].Medicinal Plant,2021,12(3):84-86.
[9] KAMEL R,LEROY J,VANDECASTEELE G,et al.Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure[J].Nature Reviews Cardiology,2023,20(2):90-108.
[10] ZHU H,XU C,DONG Y,et al.Chaigui decoction and its representative components ameliorate spontaneous hypertension rats by modulating lipid metabolism and gut microbiota[J].Journal of Ethnopharmacology,2023,305:116116.
[11] ZHU H,CHANG W,ZHOU C,et al.Chemicalome and metabolome profiling of Chaigui decoction using an integrated strategy based on Uhplc-q-tof-MS/MS analysis[J].Journal of Chromatography B,2021,1185:122979.
[12] MURRAY C J L,ARAVKIN A Y,ZHENG P,et al.Global burden of 87 risk factors in 204 countries and territories 1990-2019:A systematic analysis for the global burden of disease study 2019[J].The Lancet,2020,396(10258):1223-1249.
[13] 中华中医药学会心血管病分会.高血压中医诊疗专家共识[J].中国实验方剂学杂志,2019,25(15):217-221.
[14] 黄莉,谭辉,孙宇洁,等.当代名中医辨治高血压经验探讨[J].陕西中医药大学学报,2023,46(3):59-64.
[15] 杨映映,魏秀秀,王天铬,等.仝小林“三期六态”高血压病辨治经验[J].中华中医药杂志,2020,35(6):2949-2953.
[16] 姜依琳,舒茂宇,赵阳,等.早期高血压“型态结合”诊治模式的探索与实践[J].亚太传统医药,2023,19(8):97-101.
[17] 胡小海,朱红俊.基于运气学理论对原发性高血压的诊治新思路探讨[J].中医研究,2021,34(11):4-8.
[18] 吴金惠.当归芍药散对妊娠期高血压模型大鼠血脂相关指标的影响[J].广西中医药大学学报,2021,24(3):52-54.
[19] 朱红俊,徐辰,龚少愚,等.柴归汤对高血压小鼠血管紧张素转换酶2及肠道菌群的干预作用[J].世界中医药,2023,18(11):1547-1550,1557.
[20] FARAH C,MICHEL L Y M,BALLIGAND J L.Nitric oxide signalling in cardiovascular health and disease[J].Nature Reviews Cardiology,2018,15(5):292-316.
[21] DAS M,DEVI K P,BELWAL T,et al.Harnessing polyphenol power by targeting eNOS for vascular diseases[J].Critical Reviews in Food Science and Nutrition,2023,63(14):2093-2118.
[22] CARLSTROM M.Nitric oxide signalling in kidney regulation and cardiometabolic health[J].Nature Reviews Nephrology,2021,17(9):575-590.
[23] CANTALUPO A,SASSET L,GARGIULO A,et al.Endothelial sphingolipid de novo synthesis controls blood pressure by regulating signal transduction and NO via ceramide[J].Hypertension,2020,75(5):1279-1288.
[24] WU Y,DING Y,RAMPRASATH T,et al.Oxidative stress GTPCH1 and endothelial nitric oxide synthase uncoupling in hypertension[J].Antioxidants & Redox Signaling,2021,34(9):750-764.
[25] YU D,SONG W,TAN E Y J,et al.TIR domains of plant immune receptors are 2',3'-cAMP/cGMP synthetases mediating cell death[J].Cell,2022,185(13):2370-2386.
[26] LIU Y,CHEN J,FONTES S K,et al.Physiological and pathological roles of protein kinase A in the heart[J].Cardiovascular Research,2022,118(2):386-398.
[27] LI Y F,REN L N,GUO G,et al.Endothelial progenitor cells in ischemic stroke:An exploration from hypothesis to therapy[J].Journal of Hematology & Oncology,2015,8(1):1-17.
[28] TEJERO J,SHIVA S,GLADWIN M T.Sources of vascular nitric oxide and reactive oxygen species and their regulation[J].Physiological Reviews,2019,99(1):311-379.
[29] BELTOWSKI J.Leptin and the regulation of endothelial function in physiological and pathological conditions[J].Clinical and Experimental Pharmacology and Physiology,2012,39(2):168-178.
[30] CHISTIAKOV D A,OREKHOV A N,BOBRYSHEV Y V.Effects of shear stress on endothelial cells:Go with the flow[J].Acta Physiologica,2017,219(2):382-408.
[31] GOLLEDGE J.Update on the pathophysiology and medical treatment of peripheral artery disease[J].Nature Reviews Cardiology,2022,19(7):456-474.
[32] YANG C,TALUKDER M A H,VARADHARAJ S,et al.Early ischaemic preconditioning requires Akt and PKA-mediated activation of eNOS via serine1176 phosphorylation[J].Cardiovascular Research,2013,97(1):33-43.
[33] BIR S C,XIONG Y,KEVIL C G,et al.Emerging role of PKA/eNOS pathway in therapeutic angiogenesis for ischaemic tissue diseases[J].Cardiovascular Research,2012,95(1):7-18.

相似文献/References:

[1]杨 敏,姜钧文,肖 蕾.中医体质与急性心肌梗死及其危险因素的相关性研究*[J].陕西中医,2019,(4):437.
　YANG Min,JIANG Junwen,XIAO Lei..Study on the correlation between constitution of traditional Chinese medicine and acute myocardial infarction and its risk factors[J].,2019,(3):437.
[2]高京宏,于 龙 △,王翠娟.大秦艽汤治疗颈椎病性高血压临床研究[J].陕西中医,2019,(5):597.
　GAO Jinghong,YU Long,WANG Cuijuan..Clinical observation of Daqinjiao decoction in the treatment of cervical spondylotic hypertension[J].,2019,(3):597.
[3]侯红霞,张春红.熄风通络汤联合西药治疗对高血压患者血管内皮功能的影响*[J].陕西中医,2019,(7):875.
　HOU Hongxia,ZHANG Chunhong..Effects of Xifeng Tongluo decoction combined with western medicine on vascular endothelial function in patients with hypertension[J].,2019,(3):875.
[4]钱卫东,侍煜景△.宁脉安神颗粒治疗女性更年期高血压疗效及对患者中医证候、血压变异性的影响*[J].陕西中医,2019,(9):1202.
　QIAN Weidong,SHI Yujing..Effects of Ningmai Anshen granule on TCM syndrome and blood pressure variability in women with climacteric hypertension[J].,2019,(3):1202.
[5]郭春霞,陈震霖△.中医从心肝肾论治高血压病现代作用机制及优势探讨*[J].陕西中医,2020,(5):650.[doi:DOI:10.3969/j.issn.10007369.2020.05.027]
　GUO Chunxia,CHEN Zhenlin..Study on Modern mechanism and advantage of TCM treating hypertension on aspects of the heart,liver and kidney[J].,2020,(3):650.[doi:DOI:10.3969/j.issn.10007369.2020.05.027]
[6]钟 路,尹胡海,黄 婕,等.从热毒学说论治高血压*[J].陕西中医,2020,(8):1131.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.032]
　ZHONG Lu,YIN Huhai,HUANG Jie,et al.Treatment of hypertension by heat toxicology[J].,2020,(3):1131.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.032]
[7]朱舜明,张学军,张荣怀,等.生脉注射液联合靶剂量比索洛尔对高血压伴心力衰竭患者血管内皮功能和心功能的影响*[J].陕西中医,2020,(10):1403.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.017]
　ZHU Shunming,ZHANG Xuejun,ZHANG Ronghuai,et al.Effects of Shengmai injection combined with target dose bisoprolol on vascular endothelial function and cardiac function in patients with hypertension and heart failure[J].,2020,(3):1403.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.017]
[8]欧阳雅蓉,傅为武,黄彩依,等.自噬在高血压靶器官损害中的作用及中医药治疗研究进展*[J].陕西中医,2020,(11):1669.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.040]
[9]王辞晓,赵良斌,黄佑群.益气活血补肾方联合厄贝沙坦对高血压性肾损害患者肾功能的保护作用[J].陕西中医,2021,(6):735.[doi:DOI:10.3969/j.issn.1000-7369.2020.06.014]
　WANG Cixiao,ZHAO Liangbin,HUANG Youqun.Protective effect of Yiqi Huoxue Bushen recipe combined with irbesartan on renal function in patients with hypertensive renal damage[J].,2021,(3):735.[doi:DOI:10.3969/j.issn.1000-7369.2020.06.014]
[10]邱思婕,李新梅.平肝化痰法联合西药治疗老年高血压疗效及对患者血压变异性、臂踝脉搏波传导速度、踝臂指数的影响[J].陕西中医,2021,(8):1056.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.017]
　QIU Sijie,LI Xinmei.Clinical curative effect of Pinggan Huatan method combined with western medicine on elderly hypertension and its influences on blood pressure variability,brachial-ankle pulse wave velocity and ankle-brachial index[J].,2021,(3):1056.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.017]

备注/Memo

备注/Memo:
基金项目:国家中医药管理局第五批全国中医临床优秀人才研修项目[国中医药人教函(2022)1号]; 江苏省卫生健康委员会高层次卫生人才“六个一工程”拔尖人才项目[LGY2020025(A类)]; 江苏省无锡市“双百”中青年医疗卫生拔尖人才项目(BJ2020064)
更新日期/Last Update: 2024-03-08